Stanford Health Care’s menopause treatment page names some medicines individually while describing antidepressants as a family. That difference is meaningful. A reader should not treat the general category as confirmation that Stanford offers paroxetine, much less a specific tablet or the Brisdelle capsule discussed elsewhere on this site.
Reviewed September 29, 2026, this assessment follows the missing product question through a broader care menu. The page verifies actual menopause services and discusses several approaches. It does not give a reader a personal choice among them, prove that their existing medicines are compatible or establish the preparation a Stanford clinician would select after assessment.
Sections in this article
The published menu uses different levels of specificity
Stanford’s menopause treatment page lists antidepressants as a group and separately names fezolinetant and gabapentin. This review does not infer paroxetine from the first category or treat the named options as a recommended comparison for an individual. A general group and an exact medicine are different kinds of information.
The treatment-review questions can help turn the broad menu into a precise conversation. Which option is actually being proposed, for what concern, and with what supporting explanation? Until those details are supplied, there is no identified paroxetine product to compare with a retail listing or a capsule label.
Nonhormonal does not make every option share one purpose
The Stanford page places several nonhormonal approaches in the same broad discussion, including medicines and local lubricants or moisturizers. Their placement on one page does not establish identical effects, indications or safety requirements. The symptom and intended purpose still need to be named for the actual proposal.
The Northwestern review considers how a similarly broad clinical menu includes off-label categories without identifying an individual prescription. Here, the word nonhormonal cannot answer the product question either. This article does not recommend replacing one listed option with another or infer that a person who cannot use one treatment can automatically use the rest.
An exact capsule label is a reference, not a missing line on the menu
The separate Brisdelle label identifies a 7.5 mg paroxetine capsule for moderate to severe menopausal vasomotor symptoms. Its stated purpose does not establish that Stanford’s antidepressant category refers to this product. The quantity is included only to distinguish the referenced preparation, without providing an instruction to use it.
The capsule-and-tablet guide explains why form and identity cannot be reconstructed from a familiar ingredient. Even an exact federal label remains separate from a provider’s formulary, an individual prescription and the actual medicine dispensed. No brand, generic equivalent or pharmacy stock is confirmed for Stanford by this comparison.
Sleep assessment can be relevant without confirming a medicine explanation
Stanford’s treatment page describes access to sleep specialists and assessment for sleep disorders. That is a distinct clinical activity within the program. It does not show that poor sleep in an individual is caused by hot flashes, that an antidepressant is indicated or that a medicine already being taken explains the problem.
The UCLA review also separates overlapping symptom priorities from the purpose of a particular prescription. A professional assessment may need to address more than one question. The public menu should therefore prompt clarification rather than encourage a reader to select a medicine on the assumption that one treatment will resolve every sleep concern.
The medicine list remains necessary when several approaches are discussed
MedlinePlus explains that paroxetine has interaction concerns and that a written list should include prescription and nonprescription medicines, vitamins and supplements. A wide selection of possible treatments does not reduce the need to identify what a person already uses. Familiarity with a product is not evidence that a proposed combination is appropriate.
The full-medicine-list guide supports preparation for professional review without calculating compatibility. Stanford’s service description does not demonstrate that any reader’s list has been assessed. It also cannot establish that clinicians elsewhere have agreed to a change in a psychiatric medicine, cancer treatment or another prescription.
An unexplained change needs a clinical contact, not a self-directed experiment
The MedlinePlus information cautions about changes to paroxetine therapy and describes possible adverse effects. This is a reason to ask the treating professional how new concerns should be handled. It is not a template for testing a different amount, stopping a medicine or substituting something else from a menopause menu.
Stanford’s care description says treatment is developed around the person’s needs and includes multidisciplinary expertise. It does not publish a paroxetine-specific follow-up schedule on the reviewed page. The practical contact arrangement and responsibilities would need to come from the actual care team rather than from this educational account of available services.
Video access is a service feature with conditions still to confirm
The Stanford treatment page describes video visits and in-person locations throughout the Bay Area. This verifies that more than one visit format is discussed, but it does not guarantee that a specific person can use either format or that a prescription can be supplied across every state.
No complete visit, testing and medicine charge is established here. Access, coverage, the actual preparation and pharmacy terms remain separate questions. Stanford’s relevant clinical offering is its menopause assessment and range of treatment discussions. The paroxetine-specific boundary remains unchanged: a family name on that menu is not proof of an exact product, a prescription decision or an individual result.
Source records
Each record supports its own product, purpose and context. A service description does not establish an individual treatment outcome.
- Stanford Health Care — Menopause TreatmentsOfficial clinical service description accessed September 29, 2026. Actual menopause care is documented; a selected paroxetine product, individual prescription, pharmacy, full price and outcome are not established. · Checked 2026-09-29
- DailyMed — BRISDELLE paroxetine capsule, Legacy Pharma USA, Inc.Exact 7.5 mg capsule label, internally revised April 2025 and page updated April 28, 2025. Menopausal vasomotor indication and psychiatric-indication limitation; product-specific warnings and qualified tamoxifen interaction context. Not a provider formulary or individual dose instruction. · Checked 2026-10-21
- MedlinePlus — ParoxetineFederal patient medicine monograph covering several paroxetine forms and uses; written medicine-list, interaction, adverse-effect and professional-change context. Does not identify an individual product or supply a taper protocol. · Checked 2026-09-29